Good news for BioFirst: Further advanced on global patent.

BioFirst (6458) has signed authorization agreement with leading European Ophthalmic Pharmaceuticals to prepare for entering European market aggressively. Additional good news arrives today, its newly developed “Artificial Vitreous”, not only obtained previous patent protection approval in US, Taiwan and Australia, it’s technology receives patent protection approval in Korea with patent effective till 2030. BioFirst is one step closer to global patent protection coverage.

BioFirst’s “Artificial Vitreous” or known as” Vitreous Substitute” Technology, is the first hydrogel product used in retinal detachment repair surgery. This innovation is world-leading and has obtained patent protection in US, Australia, Taiwan and Korea. BioFirst also submitted applications to more than 10 other countries through PCT, and the patent approvals from the above 4 countries will be important index and have positive impact on obtaining approvals from other countries.

Based on market research report, the global potential market of the “Artificial Vitreous” is estimated US$2 Billion annually. BioFirst received Global authorization right from the NHRI (National Health Research Institution), obtaining patent approvals further protects and ensures market dominance. President of BioFirst, Dr. Tsung-Shann Jiang addresses: “This is a National treasure, we are going to glow across the world!” BioFirst has submitted the construction plan to the Ministry of Science and Techonologyto build the first “Artificial Vitreous” premise in the world in Hsinchu Biomedical Science Park, and will receive Global GMP certification. The production will supply global market needs, and hopefully this “Glory of Taiwan” will enlighten the window of the human soul in the world.